Today, a Director at Portola Pharma (PTLA), Charles Homcy, bought shares of PTLA for $234.2K.
This recent transaction increases Charles Homcy’s holding in the company by 18.23% to a total of $5.77 million. Following Charles Homcy’s last PTLA Buy transaction on December 19, 2018, the stock climbed by 2.5%.
See today’s analyst top recommended stocks >>
Based on Portola Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $14.18 million and GAAP net loss of $71.3 million. In comparison, last year the company earned revenue of $9.8 million and had a GAAP net loss of $91.78 million. Currently, Portola Pharma has an average volume of 2.09M. The Company has a Price to Book ratio of 7.8303.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $34.25, reflecting a 76.7% upside. Starting in November 2018, PTLA received 4 Buy ratings in a row. Three different firms, including Cowen & Co. and Oppenheimer, currently also have a Buy rating on the stock.
The insider sentiment on Portola Pharma has been positive according to 44 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Charles Homcy’s trades have generated a -13.7% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
